MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
Psychedelics Stock Warrants Offer Interesting Leverage Play
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
TSI EDITOR |
2020-09-22
Mind Cure Targets Multi-Billion Dollar Sweet-Spot in Life Sciences
The road to psychedelic drug success leads through functional mushrooms.
TSI EDITOR |
2020-09-21
Why Canada Is The Natural Launch-Pad For The Psychedelic Drug Industry
Canada stands out as the premier destination for psychedelic drug companies.
TSI EDITOR |
2020-09-19
Compass’s Upsized IPO Financing Sends ‘Buy’ Signal For Sector
Compass has boosted its IPO financing by roughly 20% AND increased the unit price -- signalling strong interest in the psychedelic space.
TSI EDITOR |
2020-09-18
An Investing Roadmap For The Mental Health Crisis
A $225 billion treatment market is badly in need of new therapies. Here is the roadmap for investors to capitalize on this opportunity.
TSI EDITOR |
2020-09-18
Functional Mushrooms: The Psychedelics Stepping Stone
Functional mushrooms are a large-and-growing health supplements market with synergies to psychedelics operations.
TSI EDITOR |
2020-09-17
Is Psilocybin More Revolutionary Than Spravato for Depression?
Spravato has not been the "game-changer" for treating depression that it was touted as being. The market remains wide open for psilocybin (and other psychedelics).
TSI EDITOR |
2020-09-14
ATAI Positioned As Kingmaker In Psychedelics Space
ATAI Life Sciences is looking more and more like the driving force in the psychedelic drug industry.
TSI EDITOR |
2020-09-09
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now